Akari Therapeutics Plc (AKTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00972G2075
Akari Therapeutics Plc financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -17.28 m USD |
| EBIT | -18.20 m USD |
| Net income | -17.30 m USD |
| Diluted EPS – continuing operations | 0.00 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Akari Therapeutics Plc
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
More stocks
- Mastercard (MA)
- BeOne Medicines Ltd. (ONC)
- Palantir Technologies (PLTR)
- AbbVie (ABBV)
- Intel (INTC)
- Tencent Holdings Ltd (700.HK)
- Cisco (CSCO)
- CXMT Corporation (688825.SS)
- Chevron Corporation (CVX)
- Costco Wholesale Corporation (COST.MX)
- Costco (COST)
- Coca-Cola Company (The) (KO)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.